Bei Ke Cai Jing·2025-07-12 13:11Core Viewpoint - The CFO of Innovent Biologics emphasized the necessity for innovative drug companies to internationalize in order to demonstrate global competitiveness, leveraging solid clinical data and rapid R&D capabilities [2][3]. Group 1: Industry Insights - The Chinese biopharmaceutical industry has seen a significant improvement in fundamentals, supported by government policies, especially from the second half of 2024 onwards, with increasing capital market attention on innovative drugs [2]. - The innovative drug sector is characterized by long investment timelines and high risks, necessitating patient capital to support industry growth [4]. - The establishment of a diversified payment system for innovative drugs will provide systematic support for patients to access high-quality medications, reinforcing the institutional foundation for high-quality development in China's innovative drug industry [4]. Group 2: Company Development - Innovent Biologics, founded in 2015, has evolved into a comprehensive biopharmaceutical enterprise with capabilities in source innovation, clinical development, production, and commercialization [3]. - The company is currently in its 2.0 rapid development phase, with two products already approved for market, and plans to diversify and internationalize its product offerings [3]. - Innovent aims to expand from hematological oncology into solid tumors and autoimmune diseases, addressing significant medical needs in conditions like atopic dermatitis and vitiligo, ensuring accelerated growth over the next 5 to 10 years [3].